251 related articles for article (PubMed ID: 27298504)
1. Atypical post-finasteride syndrome: A pharmacological riddle.
Gupta AK; Sharma N; Shukla P
Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
[TBL] [Abstract][Full Text] [Related]
2. Androgenetic alopecia; drug safety and therapeutic strategies.
Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
[TBL] [Abstract][Full Text] [Related]
3. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
Fertig RM; Gamret AC; Darwin E; Gaudi S
Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
[TBL] [Abstract][Full Text] [Related]
4. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors.
Coskuner ER; Ozkan B; Culha MG
Sex Med Rev; 2019 Apr; 7(2):277-282. PubMed ID: 30301703
[TBL] [Abstract][Full Text] [Related]
5. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.
Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B
World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745
[TBL] [Abstract][Full Text] [Related]
7. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
[TBL] [Abstract][Full Text] [Related]
8. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
Shanshanwal SJ; Dhurat RS
Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
[TBL] [Abstract][Full Text] [Related]
9. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
Gupta AK; Talukder M; Williams G
J Dermatolog Treat; 2022 Nov; 33(7):2946-2962. PubMed ID: 35920739
[TBL] [Abstract][Full Text] [Related]
10. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
11. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.
Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G
J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride in Androgenetic Alopecia: An Update.
Arif T; Dorjay K; Adil M; Sami M
Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
[TBL] [Abstract][Full Text] [Related]
13. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S; Lee YB; Choe SJ; Lee WS
Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
[TBL] [Abstract][Full Text] [Related]
14. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
Cecchin E; De Mattia E; Mazzon G; Cauci S; Trombetta C; Toffoli G
Int J Biol Markers; 2014 Dec; 29(4):e310-6. PubMed ID: 24855036
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
16. Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia.
Courtney A; Triwongwarant D; Chim I; Eisman S; Sinclair R
Expert Opin Pharmacother; 2023; 24(18):1919-1922. PubMed ID: 37942878
[No Abstract] [Full Text] [Related]
17. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
[TBL] [Abstract][Full Text] [Related]
18. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
Arias-Santiago S; Camacho-Martínez FM
Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
[No Abstract] [Full Text] [Related]
19. Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
Seale LR; Eglini AN; McMichael AJ
J Drugs Dermatol; 2016 Apr; 15(4):414-9. PubMed ID: 27050696
[TBL] [Abstract][Full Text] [Related]
20. Post-finasteride syndrome: a surmountable challenge for clinicians.
Traish AM
Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
